Arbutus Biopharma Corp
ABUSArbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ABUS Earnings Report
FQ end 2026-06
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TKM-080301 | Phase 2 | Cancer | - | - |
ARB-001467 | Phase 2 | Hepatitis B, Chronic | - | - |
AB-729 | Phase 2 | Chronic Hepatitis b | - | - |
Cancer
1 drug in this indication
Chronic Hepatitis b
1 drug in this indication
Hepatitis B, Chronic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arbutus Biopharma Corp's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Arbutus Biopharma Corp's (ABUS) pipeline across Phase 2. Its lead program is TKM-080301 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arbutus Biopharma Corp's next FDA catalyst?→
Arbutus Biopharma Corp's (ABUS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABUS biotech catalysts?→
Add ABUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arbutus Biopharma Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.